Core Viewpoint - Vivos Therapeutics, Inc. is set to release its full year 2024 financial results on March 31, 2025, and will hold a conference call to discuss these results and recent developments [1] Company Overview - Vivos Therapeutics, Inc. specializes in medical devices and technology for treating sleep-related breathing disorders, including obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6 to 17 [1][4] - The Vivos Method is a clinically effective, nonsurgical, noninvasive, and cost-effective solution for treating OSA, having been proven effective in approximately 58,000 patients treated worldwide by over 2,000 trained dentists [4][5] Treatment Methodology - The Vivos Method employs proprietary CARE appliance therapy and other modalities to alter the size, shape, and position of the jaw and soft tissues in the upper airway, significantly reducing symptoms associated with OSA [5] - Vivos also markets SleepImage diagnostic technology for home sleep testing under its VivoScore program, and offers training and services to dentists through its Vivos Integrated Practice (VIP) program [5] Conference Call Details - The conference call to discuss the financial results will take place at 5:00 p.m. (Eastern Time) on March 31, 2025, with access available via phone and a live webcast on the company's website [1][2][3]
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call